Jiang et al. developed in 2015 a formulation of crizotinib (EML4-ALK fusion positive lung cancer) and polylactic tocopheryl PEG 1000 succinate (PLA-TPGS), which showed sustained release, induced cytotoxicity in NCIH3122 lung cancer cells and perceptible early and late apoptosis [75]. This evidence concerns the gene ALK and lung carcinoma.